2 documents found, page 1 of 1
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
Connolly, SJ; Sharma, M; Cohen, AT; Demchuk, AM; Czlonkowska, A; Lindgren, AG; Molina, CA; Bereczki, D; Toni, D; Seiffge, DJ; Tanne, D; Sandset, EC"Background: Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied. Methods: We randomly assigned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an acute intrac...
Global Impact of COVID-19 on Stroke Care and IV Thrombolysis
Nogueira, RG; Qureshi, MM; Abdalkader, M; Martins, SO; Yamagami, H; Qiu, Z; Mansour, OY; Sathya, A; Czlonkowska, A; Tsivgoulis, G; Aguiar de Sousa, DObjective: To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods. Methods: We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified ...